Brief: Pmv Pharmaceuticals Announces Clinical Trial Collaboration With Merck To Evaluate PC14586 In Combination With Keytruda In Patients With Advanced Solid Tumors

Pmv Pharmaceuticals

18/07/2022 14:07

July 18 (Reuters) - PMV Pharmaceuticals Inc  PMVP.O :
    * PMV PHARMACEUTICALS ANNOUNCES A CLINICAL TRIAL
COLLABORATION
WITH MERCK TO EVALUATE PC14586 IN COMBINATION WITH KEYTRUDA®
(PEMBROLIZUMAB) IN PATIENTS WITH ADVANCED SOLID TUMORS
    * PMV PHARMACEUTICALS -  ENTERED CLINICAL TRIAL
COLLABORATION AND
SUPPLY AGREEMENT WITH MERCK TO EVALUATE PC14586 IN COMBINATION
WITH MERCK'S KEYTRUDA
    * PMV PHARMACEUTICALS INC - WILL EVALUATE PC14586 IN
COMBINATION
WITH KEYTRUDA AS A SEPARATE ARM OF COMPANY'S ONGOING PHASE 1/2
PYNNACLE TRIAL

Source text for Eikon:  ID:nGNXCKs5X 
Further company coverage:  PMVP.O 

 ((Reuters.Briefs@thomsonreuters.com;))